The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination
- PMID: 10635029
- DOI: 10.1007/978-1-4615-4685-6_15
The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination
Abstract
Remyelination enables restoration of saltatory conduction and a return of normal function lost during demyelination. Unfortunately, remyelination is often incomplete in the adult human central nervous system (CNS) and this failure of remyelination is one of the main reasons for clinical deficits in demyelinating disease. An understanding of the failure of remyelination in demyelinating diseases such as Multiple Sclerosis depends upon the elucidation of cellular events underlying successful remyelination. Although the potential for remyelination of the adult CNS has been well established, there is still some dispute regarding the origin of the remyelinating cell population. The literature variously reports that remyelinating oligodendrocytes arise from dedifferentiation and/or proliferation of mature oligodendrocytes, or are generated solely from proliferation and differentiation of glial progenitor cells. This review focuses on studies carried out on remyelinating lesions in the adult rat spinal cord produced by injection of antibodies to galactocerebroside plus serum complement that demonstrate: 1) oligodendrocytes which survive within an area of demyelination do not contribute to remyelination, 2) remyelination is carried out by oligodendrocyte progenitor cells, 3) recruitment of oligodendrocyte progenitors to an area of demyelination is a local response, and 4) division of oligodendrocyte progenitors is symmetrical and results in chronic depletion of the oligodendrocyte progenitor population in the normal white matter around an area of remyelination. These results suggest that failure of remyelination may be contributed to by a depletion of oligodendrocyte progenitors especially following repeated episodes of demyelination. Remyelination allows the return of saltatory conduction (Smith et al., 1979) and the functional recovery of demyelination-induced deficits (Jeffery et al., 1997). Findings such as these have encouraged research aimed at enhancing the limited remyelination found in Multiple Sclerosis (MS) lesions, evidenced by a rim of thin myelin sheaths around the edges of a lesion, or, in a minority of acute foci, throughout the entire lesion (Prineas et al., 1989; Raine et al., 1981). It must be said, however, that although remyelination is clearly a prerequisite to sustained functional recovery, other factors such as the state of the inflammatory response and degree of axonal survival within the demyelinated region contribute to the extent of functional recovery that may be possible following therapeutic intervention aimed at halting disease progression. It is not yet clear whether the progression of functional deficits in MS is primarily the result of an increasing load of demyelination, or axon loss, or a combination of the two processes. However, given the increasing recognition that myelin sheaths play a role in protecting axons from degeneration, the success or failure of remyelination has functional consequences for the patient. To understand why remyelination should fail in demyelinating disease and develop strategies to enhance remyelination requires an understanding of the biology of successful remyelination. Firstly, what is the origin of the remyelinating cell population in the adult CNS? Secondly, what are the dynamics of the cellular response of this population during demyelination and remyelination? And thirdly, what are the consequences to the tissue of an episode of demyelination? This review will focus on studies that address these issues, and discuss the implications of the results of these experiments for our understanding of MS and the development of therapeutic interventions aimed at enhancing remyelination.
Similar articles
-
The origin of remyelinating cells in the central nervous system.J Neuroimmunol. 1999 Jul 1;98(1):69-76. doi: 10.1016/s0165-5728(99)00083-1. J Neuroimmunol. 1999. PMID: 10426364 Review.
-
Inflammation stimulates remyelination in areas of chronic demyelination.Brain. 2005 Mar;128(Pt 3):528-39. doi: 10.1093/brain/awh417. Epub 2005 Feb 7. Brain. 2005. PMID: 15699059
-
The remyelinating potential and in vitro differentiation of MOG-expressing oligodendrocyte precursors isolated from the adult rat CNS.Eur J Neurosci. 2004 Sep;20(6):1445-60. doi: 10.1111/j.1460-9568.2004.03606.x. Eur J Neurosci. 2004. PMID: 15355312
-
Impaired remyelination and depletion of oligodendrocyte progenitors does not occur following repeated episodes of focal demyelination in the rat central nervous system.Brain. 2003 Jun;126(Pt 6):1382-91. doi: 10.1093/brain/awg126. Brain. 2003. PMID: 12764059
-
Do central nervous system axons remyelinate?Pathol Biol (Paris). 2000 Feb;48(1):70-9. Pathol Biol (Paris). 2000. PMID: 10729914 Review.
Cited by
-
Combination of electroacupuncture and grafted mesenchymal stem cells overexpressing TrkC improves remyelination and function in demyelinated spinal cord of rats.Sci Rep. 2015 Mar 16;5:9133. doi: 10.1038/srep09133. Sci Rep. 2015. PMID: 25779025 Free PMC article.
-
Effects of the transcription factor Olig1 on the differentiation and remyelination of oligodendrocyte precursor cells after focal cerebral ischemia in rats.Mol Med Rep. 2019 Nov;20(5):4603-4611. doi: 10.3892/mmr.2019.10713. Epub 2019 Sep 26. Mol Med Rep. 2019. PMID: 31702031 Free PMC article.
-
Increased oligodendrogenesis and myelination in the subventricular zone of aged mice and gray mouse lemurs.Stem Cell Reports. 2023 Feb 14;18(2):534-554. doi: 10.1016/j.stemcr.2022.12.015. Epub 2023 Jan 19. Stem Cell Reports. 2023. PMID: 36669492 Free PMC article.
-
Induction of oligodendrocyte differentiation and in vitro myelination by inhibition of rho-associated kinase.ASN Neuro. 2014 Jun 25;6(4):1759091414538134. doi: 10.1177/1759091414538134. ASN Neuro. 2014. PMID: 25289646 Free PMC article.
-
Cellular Pharmacological Effects of the Traditional Japanese Kampo Medicine Yokukansan on Brain Cells.Front Pharmacol. 2017 Sep 20;8:655. doi: 10.3389/fphar.2017.00655. eCollection 2017. Front Pharmacol. 2017. PMID: 28979206 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical